Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 7/20 | 0.70 |
| ▸ | GABRA5 | P31644 | 7/20 | 0.70 |
| ▸ | GABRA2 | P47869 | 7/20 | 0.70 |
| ▸ | GABRG2 | P18507 | 6/20 | 0.70 |
| ▸ | GABRB3 | P28472 | 6/20 | 0.70 |
| ▸ | GABRA3 | P34903 | 6/20 | 0.70 |
| ▸ | GABRB2 | P47870 | 5/20 | 0.70 |
| ▸ | GABRP | O00591 | 1/20 | 0.70 |
| ▸ | GABRD | O14764 | 1/20 | 0.70 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.70 |
| ▸ | ALB | P02768 | 1/20 | 0.70 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.70 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.70 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.70 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.70 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.70 |
| ▸ | GABRE | P78334 | 1/20 | 0.70 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.70 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.70 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5042664 | 0.92 | GABRA1 (0.65) | GABRA1GABRA5GABRA2GABRG2GABRB3 | |
| SCHEMBL5357877 | 0.90 | GABRA1 (0.67) | GABRA1GABRA5GABRA2GABRG2GABRB3 | |
| SCHEMBL5042437 | 0.87 | GABRA1 (0.60) | GABRA1GABRA5GABRA2GABRG2GABRB3 | |
| SCHEMBL11771458 | 0.87 | GABRA1 (0.63) | GABRA1GABRA5GABRA2GABRG2GABRB3 | |
| SCHEMBL6028757 | 0.85 | PDE2A (0.64) | GABRA1GABRA5GABRA2GABRG2GABRB3 | |
| SCHEMBL5360424 | 0.84 | PDE2A (0.66) | GABRA1GABRA5GABRA2GABRG2GABRB3 | |
| SCHEMBL24194446 | 0.83 | GABRA1 (0.74) | GABRA1GABRA5GABRA2GABRG2GABRB3 | |
| SCHEMBL607255 | 0.83 | LMNA (0.81) | GABRA1GABRA5GABRA2GABRG2GABRB3 | |
| SCHEMBL11681384 | 0.82 | GABRA1 (1.00) | GABRA1GABRA5GABRA2GABRG2GABRB3 | |
| SCHEMBL2928346 | 0.82 | GABRA1 (0.73) | GABRA1GABRA5GABRA2GABRG2GABRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040152888-A1 | Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses thereof | BAY CITY CAPITAL LLC | 2004-08-05 | — | — | US | claimed |
| US-7250410-B2 | Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses thereof | VIA PHARMACEUTICALS, INC. (US) | 2007-07-31 | — | — | US | disclosed |
| US-20040152888-A1 | Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses thereof | BAY CITY CAPITAL LLC | 2004-08-05 | — | — | US | disclosed |
| EP-1392663-A2 | CYCLIC NUCLEOTIDE PHOSPHODIESTERASE INHIBITORS, PREPARATION AND USES THEREOF | NEURO3D (FR) | 2004-03-03 | — | — | EP | disclosed |
| WO-2002098865-A2 | CYCLIC NUCLEOTIDE PHOSPHODIESTERASE INHIBITORS, PREPARATION AND USES THEREOF | NEURO3D (FR) | 2002-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152888-A1 | Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses thereof | PDE7A, PDE3B, PDE3A | GABRA1 92/4885GABRA5 98/4885GABRA2 137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.